Roche, Tecentriq
Stories on US FDA approving injectable Roche multiple sclerosis therapy are withdrawn
The U.S. Food and Drug Administration on Thursday approved Roche's under-the-skin injection to treat patients with multiple sclerosis.
Roche doubles down with another subcutaneous FDA nod, this one for MS star Ocrevus
When Roche's Genentech gained approval for Ocrevus in 2017, the first-in- | On the same day that Roche gained an FDA approval for its subcutaneous version of cancer drug Tecentriq, the company also scored with a U.
FDA approves Roche’s injectable version of blockbuster multiple sclerosis drug
Patients will be able to get a 10 minute injection of the Roche drug, instead of an hours-long infusion. Novartis already has its own injectable MS drug, Kesimpta.
US FDA approves injectable version of Roche's multiple sclerosis therapy
The U.S. Food and Drug Administration on Friday approved Roche's under-the-skin injection to treat patients with multiple sclerosis. The subcutaneous or under-the-skin therapy called Ocrevus Zunovo has the potential to expand treatment options to centers unable to administer the IV version.
Roche Gets FDA Approval for Multiple-Sclerosis Treatment
Roche Holding's Genentech unit said the Food and Drug Administration approved its twice-yearly, subcutaneous injection treatment for patients with two types of multiple sclerosis. The treatment, called Ocrevus Zunovo,
Roche Gets FDA Approval for Subcutaneous Formulation of Tecentriq
Roche RHHBY announced that the FDA has approved the subcutaneous (SC) formulation of the blockbuster immunotherapy drug Tecentriq (atezolizumab). The SC formulation was approved under the brand name Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs).
Roche shares knocked by concern over side effects in obesity pill trial
Shares in Roche dropped to a two-month low on Thursday after an experimental weight-loss pill that carries high market hopes ...
FierceBiotech3d
‘The trajectory is encouraging.’ Roche hopes obesity drug will show 25% weight loss one day
Roche is holding out hopes that its injectable obesity prospect could eventually demonstrate 25% weight loss in late-stage ...
Viking Therapeutics: A Bad Result for Roche's Weight-Management Pill Is Great News for Oral VK2735
Recently revealed trial results for Roche's experimental weight-management drug suggest Viking Therapeutics is on the right ...
Roche Not Alarmed by Obesity Drug’s Side Effects, R&D Head Says
Roche Holding AG said it isn’t concerned about side effects in a small study of a weight-loss shot, after details about the ...
Roche's Manu Chakravarthy talks weight loss drug trial results
Weight loss injections are popular among adults, but a new study suggest they could be useful in fighting childhood obesity, ...
ENDPOINTS NEWS1d
FDA ap­proves sub­cu­ta­neous Ocre­vus, broad­en­ing ac­cess to Roche and Genen­tech block­buster
The FDA on Friday approved a new formulation of Roche and Genentech’s multiple sclerosis drug Ocrevus in what they hope will ...
Roche Says Obesity Pill’s Side Effects Blunted by Gradual Dosing
Roche Holding AG said side effects in a highly anticipated study of its experimental obesity pill were milder when it eased ...
FierceBiotech3d
Roche ramps up R&D with $1.4B Swiss facility
Roche’s R&D is moving on up. The pharma giant has opened two new high-rises in Basel, Switzerland, according to a Sept. 10 ...
Roche Bobois RBO Cuts Sales Guidance for 2024 on ‘Less Than Buoyant' Market
First-half sales fell in key markets like the U.S. and the upscale French furniture-maker revised its forecasts down, citing ...